Scott Smith

Scott has held leadership positions at many neurotechnology companies, including Neuroscan,
Compumedics, EmSense, Neuralynx, and Diagnostic Biochips. Scott was part of the team who brought the first commercial 128 channel amplifier to market (Neuroscan Synamp), and the first FDA approved 512 channel system for recording from microelectrodes in humans (Neuralynx ATLAS). He has extensive expertise in equipping pre-clinical research studies, including human single-neuron studies. Scott is passionate about enabling research by scientists and clinicians at many of the world’s leading academic facilities.